•The U.S. FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cytisinicline for nicotine dependence.
•The rejection was due to manufacturing-related observations at a third-party facility and incomplete product labeling, not clinical safety or efficacy issues.